CA2764370C - Fucosylation-deficient cells - Google Patents

Fucosylation-deficient cells Download PDF

Info

Publication number: CA2764370C
Authority: CA; Canada
Prior art keywords: cell; glycoprotein; protein; modification; amino acid
Prior art date: 2009-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2764370A

Other languages

English (en)

French (fr)

Other versions

CA2764370A1 (en

Inventor

Gang Chen

Darya Burakov

James P. Fandl

Original Assignee

Regeneron Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-02

Filing date

2010-06-01

Publication date

2018-08-21

2010-06-01 Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc

2010-12-09 Publication of CA2764370A1 publication Critical patent/CA2764370A1/en

2018-08-21 Application granted granted Critical

2018-08-21 Publication of CA2764370C publication Critical patent/CA2764370C/en

Status Active legal-status Critical Current

2030-06-01 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA2764370A 2009-06-02 2010-06-01 Fucosylation-deficient cells Active CA2764370C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US18340009P	2009-06-02	2009-06-02
US61/183,400		2009-06-02
US34885810P	2010-05-27	2010-05-27
US61/348,858		2010-05-27
PCT/US2010/036914 WO2010141478A1 (en)	2009-06-02	2010-06-01	Fucosylation-deficient cells

Publications (2)

Publication Number	Publication Date
CA2764370A1 CA2764370A1 (en)	2010-12-09
CA2764370C true CA2764370C (en)	2018-08-21

Family

ID=42338231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2764370A Active CA2764370C (en)	2009-06-02	2010-06-01	Fucosylation-deficient cells

Country Status (16)

Country	Link
US (8)	US8409838B2 (2)
EP (3)	EP2808393B1 (2)
JP (4)	JP5744856B2 (2)
KR (2)	KR101441437B1 (2)
CN (1)	CN102459603B (2)
AU (1)	AU2010256753B2 (2)
BR (1)	BRPI1010035A2 (2)
CA (1)	CA2764370C (2)
DK (3)	DK2438171T3 (2)
ES (2)	ES2661074T3 (2)
HU (1)	HUE038596T2 (2)
IL (1)	IL216624A (2)
PL (3)	PL2808393T3 (2)
SG (1)	SG176251A1 (2)
TW (1)	TWI513818B (2)
WO (1)	WO2010141478A1 (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140161782A1 (en)	2008-06-09	2014-06-12	Targazyme, Inc.	Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
DK2438171T3 (en)	2009-06-02	2015-01-26	Regeneron Pharma	Fucosylerings-deficient cells
WO2012120500A2 (en)	2011-03-06	2012-09-13	Merck Serono S.A.	Low fucose cell lines and uses thereof
WO2013013013A2 (en) *	2011-07-21	2013-01-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for producing modified glycoproteins
TW201823460A (zh)	2012-05-29	2018-07-01	美商再生元醫藥公司	生產細胞株增強子
EP2722673B1 (en)	2012-10-17	2017-07-12	Hexal AG	Improved method of mapping glycans of glycoproteins
AR095196A1 (es)	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
WO2015033343A1 (en)	2013-09-03	2015-03-12	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Compositions and methods for expressing recombinant polypeptides
WO2015057393A1 (en) *	2013-10-01	2015-04-23	University Of Wyoming	Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins
AU2015229591B2 (en)	2014-03-11	2020-10-22	Regeneron Pharmaceuticals, Inc.	Anti-EGFRvlll antibodies and uses thereof
EP3149034B1 (en) *	2014-05-30	2022-07-13	New England Biolabs, Inc.	Deglycosylation reagents and methods
WO2016007506A1 (en) *	2014-07-07	2016-01-14	Targazyme, Inc.	Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) *	2014-11-20	2019-08-23	中国人民解放军军事医学科学院生物工程研究所	用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh)	2015-01-26	2020-11-21	美商再生元醫藥公司	抗伊波拉病毒醣蛋白之人類抗體
TW202440904A (zh)	2015-08-04	2024-10-16	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法（二）
WO2017079165A1 (en) *	2015-11-02	2017-05-11	Genentech, Inc.	Methods of making fucosylated and afucosylated forms of a protein
US20190161543A1 (en) *	2016-01-06	2019-05-30	Outlook Therapeutics, Inc.	Modulation of afucosylated species in a monoclonal antibody composition
CN109563161A (zh)	2016-02-03	2019-04-02	安口生物公司	用于提高抗体稳定性的缓冲制剂
US11512144B2 (en) *	2016-04-20	2022-11-29	Regeneran Pharmaceuticals, Inc.	Compositions and methods for making antibodies based on use of an expression-enhancing loci
EA201892137A1 (ru)	2016-04-20	2019-03-29	Регенерон Фармасьютикалз, Инк.	Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EP3339444A1 (en) *	2016-12-20	2018-06-27	Mabxience Research, S.L.	Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
BR112020019559A2 (pt)	2018-03-26	2021-01-12	Amgen Inc.	Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
EP3818149A4 (en) *	2018-08-29	2022-03-23	United Biopharma Inc	Afucosylated antibodies and manufacture thereof
WO2020090747A1 (ja)	2018-10-29	2020-05-07	株式会社免疫生物研究所	抗ｈｉｖ抗体及びその製造方法
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
JP2023527352A (ja)	2020-05-26	2023-06-28	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体及び抗原結合断片
CA3181026A1 (en)	2020-06-03	2021-12-09	Samit GANGULY	Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN112843234B (zh) *	2021-01-20	2022-09-06	四川大学华西第二医院	一种调控生物机体内gdp-甘露糖的浓度的装置
EP4352094A1 (en)	2021-06-07	2024-04-17	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
EP4359440A1 (en)	2021-06-22	2024-05-01	Regeneron Pharmaceuticals, Inc.	Anti-egfrviii antibody drug conjugates and uses thereof
IL310012A (en)	2021-07-14	2024-03-01	Regeneron Pharma	Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023081434A2 (en)	2021-11-07	2023-05-11	Regeneron Pharmaceuticals, Inc.	Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
WO2023167847A2 (en)	2022-03-02	2023-09-07	Regeneron Pharmaceuticals, Inc.	Bioreactor for antibody production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1006070A (en)	1909-05-11	1911-10-17	George Walter Durbrow	Method of and means for extracting micro-organisms and solids from water.
EP1176195B1 (en)	1999-04-09	2013-05-22	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
JP2001145488A (ja)	1999-11-19	2001-05-29	Natl Inst Of Advanced Industrial Science & Technology Meti	シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子
FR2807767B1 (fr)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
ES2639222T5 (es) *	2000-10-06	2023-11-24	Kyowa Kirin Co Ltd	Células que producen unas composiciones de anticuerpo
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en)	2001-01-10	2002-10-17	Wang Peng G.	Glycoconjugate and sugar nucleotide synthesis using solid supports
WO2002057423A2 (en)	2001-01-16	2002-07-25	Regeneron Pharmaceuticals, Inc.	Isolating cells expressing secreted proteins
HUP0600342A3 (en)	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
KR100585140B1 (ko)	2004-04-26	2006-05-30	삼성전자주식회사	와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) *	2004-08-05	2006-10-05	Kyowa Hakko Kogyo Co., Ltd.,	Process for producing glycoprotein composition
US20090208500A1 (en)	2005-06-03	2009-08-20	Genentech, Inc.	Method of producing antibodies with improved function
PL2383297T3 (pl)	2006-08-14	2013-06-28	Xencor Inc	Zoptymalizowane przeciwciała ukierunkowane na CD19
AU2008227024A1 (en)	2007-03-07	2008-09-18	Glycofi, Inc.	Production of glycoproteins with modified fucosylation
WO2008151219A1 (en)	2007-06-04	2008-12-11	Regeneron Pharmaceuticals, Inc.	Enhanced expression and stability regions
JP5662149B2 (ja)	2008-08-13	2015-01-28	協和発酵キリン株式会社	遺伝子組換えプロテインｓ組成物
DK2438171T3 (en)	2009-06-02	2015-01-26	Regeneron Pharma	Fucosylerings-deficient cells
WO2012120500A2 (en)	2011-03-06	2012-09-13	Merck Serono S.A.	Low fucose cell lines and uses thereof

2010
- 2010-06-01 DK DK10721096.5T patent/DK2438171T3/en active
- 2010-06-01 CN CN2010800294912A patent/CN102459603B/zh not_active Expired - Fee Related
- 2010-06-01 AU AU2010256753A patent/AU2010256753B2/en not_active Ceased
- 2010-06-01 DK DK14179885.0T patent/DK2808393T3/en active
- 2010-06-01 PL PL14179885T patent/PL2808393T3/pl unknown
- 2010-06-01 HU HUE14179885A patent/HUE038596T2/hu unknown
- 2010-06-01 EP EP14179885.0A patent/EP2808393B1/en active Active
- 2010-06-01 DK DK17192430.1T patent/DK3279326T3/da active
- 2010-06-01 CA CA2764370A patent/CA2764370C/en active Active
- 2010-06-01 KR KR1020117031320A patent/KR101441437B1/ko not_active Expired - Fee Related
- 2010-06-01 PL PL17192430T patent/PL3279326T3/pl unknown
- 2010-06-01 US US12/791,637 patent/US8409838B2/en active Active
- 2010-06-01 EP EP17192430.1A patent/EP3279326B1/en active Active
- 2010-06-01 BR BRPI1010035-0A patent/BRPI1010035A2/pt not_active Application Discontinuation
- 2010-06-01 PL PL10721096T patent/PL2438171T3/pl unknown
- 2010-06-01 KR KR1020147007025A patent/KR101641526B1/ko not_active Expired - Fee Related
- 2010-06-01 ES ES14179885.0T patent/ES2661074T3/es active Active
- 2010-06-01 SG SG2011087517A patent/SG176251A1/en unknown
- 2010-06-01 WO PCT/US2010/036914 patent/WO2010141478A1/en not_active Ceased
- 2010-06-01 ES ES10721096.5T patent/ES2527173T3/es active Active
- 2010-06-01 EP EP10721096.5A patent/EP2438171B1/en active Active
- 2010-06-01 TW TW099117652A patent/TWI513818B/zh not_active IP Right Cessation
- 2010-06-01 JP JP2012514045A patent/JP5744856B2/ja not_active Expired - Fee Related
2011
- 2011-11-27 IL IL216624A patent/IL216624A/en active IP Right Grant
2013
- 2013-02-28 US US13/779,952 patent/US9206455B2/en active Active
2014
- 2014-12-12 JP JP2014251541A patent/JP2015051021A/ja not_active Withdrawn
2015
- 2015-12-08 US US14/963,178 patent/US9550823B2/en active Active
2016
- 2016-03-07 JP JP2016043151A patent/JP6211642B2/ja not_active Expired - Fee Related
- 2016-10-14 JP JP2016202634A patent/JP2017006147A/ja active Pending
- 2016-12-14 US US15/378,670 patent/US10006070B2/en active Active
2018
- 2018-05-23 US US15/987,286 patent/US20190024129A1/en not_active Abandoned
2019
- 2019-08-30 US US16/556,334 patent/US20200080124A1/en not_active Abandoned
2021
- 2021-05-04 US US17/307,255 patent/US11560550B2/en active Active
2022
- 2022-12-15 US US18/066,303 patent/US12054751B2/en active Active

Also Published As

Publication number	Publication date
US20200080124A1 (en)	2020-03-12
TW201107469A (en)	2011-03-01
ES2661074T3 (es)	2018-03-27
JP2012528594A (ja)	2012-11-15
CN102459603B (zh)	2013-11-06
CA2764370A1 (en)	2010-12-09
IL216624A0 (en)	2012-02-29
HK1163745A1 (en)	2012-09-14
JP6211642B2 (ja)	2017-10-11
PL3279326T3 (pl)	2021-03-08
HK1198180A1 (en)	2015-03-13
US12054751B2 (en)	2024-08-06
EP3279326B1 (en)	2020-10-14
CN102459603A (zh)	2012-05-16
TWI513818B (zh)	2015-12-21
DK3279326T3 (da)	2020-12-21
US20100304436A1 (en)	2010-12-02
US20230295583A1 (en)	2023-09-21
US10006070B2 (en)	2018-06-26
EP3279326A1 (en)	2018-02-07
IL216624A (en)	2015-02-26
US9550823B2 (en)	2017-01-24
JP2017006147A (ja)	2017-01-12
KR20140039340A (ko)	2014-04-01
JP5744856B2 (ja)	2015-07-08
KR101441437B1 (ko)	2014-09-25
WO2010141478A1 (en)	2010-12-09
EP2438171A1 (en)	2012-04-11
US20190024129A1 (en)	2019-01-24
AU2010256753B2 (en)	2013-11-28
AU2010256753A1 (en)	2012-01-12
US9206455B2 (en)	2015-12-08
US20210254022A1 (en)	2021-08-19
PL2808393T3 (pl)	2018-04-30
JP2016104045A (ja)	2016-06-09
SG176251A1 (en)	2011-12-29
EP2808393A3 (en)	2015-03-11
US20130164786A1 (en)	2013-06-27
US20160090410A1 (en)	2016-03-31
DK2808393T3 (en)	2018-03-12
BRPI1010035A2 (pt)	2015-08-25
EP2808393A2 (en)	2014-12-03
US20170211115A1 (en)	2017-07-27
EP2438171B1 (en)	2014-12-17
JP2015051021A (ja)	2015-03-19
US11560550B2 (en)	2023-01-24
HK1249547A1 (en)	2018-11-02
ES2527173T3 (es)	2015-01-21
US8409838B2 (en)	2013-04-02
KR101641526B1 (ko)	2016-07-21
HUE038596T2 (hu)	2018-10-29
PL2438171T3 (pl)	2015-04-30
EP2808393B1 (en)	2018-01-10
KR20120029443A (ko)	2012-03-26
DK2438171T3 (en)	2015-01-26

Legal Events

Date	Code	Title	Description
2015-04-02	EEER	Examination request	Effective date: 20150320
2025-12-15	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251215
2025-12-24	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251224
2026-03-30	H13	Ip right lapsed	Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260330
2026-04-07	H13	Ip right lapsed	Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260407